[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387393":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":24,"responsibleParty":40,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Yongchang Zhang","Hunan Cancer Hospital","PRINCIPAL_INVESTIGATOR",[14,20],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Yongchang Zhang, MD","CONTACT","+8613873123436","7+861383123436","zhangyongchang@csu.edu.cn",{"name":21,"role":16,"phone":22,"phoneExt":17,"email":23},"Nong Yang, MD","+8613055193557","yangnong0217@163.com",[25],{"facility":10,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Changsha","Hunan","410013","China","CN",{"type":33,"coordinates":34},"Point",[35,36],112.97087,28.19874,{"lat":36,"lon":35},[39],{"name":15,"role":16,"phone":17,"phoneExt":17,"email":19},{"type":12,"investigatorFullName":10,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"professor","100387393","pembrolizumab-combined-with-double-platinum-based-chemotherapy-for-potentially-resectable-nsclc-100387393",false,"NCT04324151","Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC","Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology\n* Potentially Resectable NSCLC\n* Treatment Plan is Crizotinb or Standard Chemotherapy\n\nExclusion Criteria:\n\n* Patients with contraindication of chemotherapy\n* Pregnant or breast feeding women","ALL","18 Years",{"count":52,"type":53},70,"ESTIMATED","OBSERVATIONAL","This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer",[57],"Non Small Cell Lung Cancer","2024-09-17",{"date":60,"type":61},"2024-09-19","ACTUAL",{"date":63,"type":61},"2020-03-24",{"date":65,"type":53},"2025-03-24",{"name":5,"class":6},1]